Just recently, Wang-Gillam et al. designed a phase I dose-escalation and expansion study to explore the efficacy and safety of a FAK inhibitor (defactinib) in combination with pembrolizumab and Gem in previously treated patients with advanced pancreatic cancer. Here, PTK2 is linked to pancreatic neoplasm.